Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

Study Summary

This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD who have an inadequate response to ongoing GAD treatment.

Conditions

Generalized Anxiety Disorder

Interventions / Drugs

ITI-1284 10 mg ITI-1284 20 mg Placebo

View on ClinicalTrials.gov ↗

Sponsor

ITCI

Intra-Cellular Therapies

Neuroscience

F29/100

Study Details

Enrollment705 participants

Primary Completion—

Lead SponsorIntra-Cellular Therapies, Inc.

Data Retrieved2026-04-11 04:18:13.264732+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.